US 12,227,540 B2
Saponin purification
Ahmad Taimour Baig, Hamilton, MT (US); Felicie Georgette Colette Denet, Pompey, NY (US); Juan Jose Diaz Garcia, Marietta, PA (US); Chad Austin Farrenburg, Hamilton, MT (US); Lora Lea Lawrence, Hamilton, MT (US); Kent Raymond Myers, Hamilton, MT (US); Jeri Kay Sandvick, Hamilton, MT (US); and Jeb Yeatts Vandenburg, Hamilton, MT (US)
Assigned to GlaxoSmithKline Biologicals SA, Rixensart (BE)
Filed by GLAXOSMITHKLINE BIOLOGICALS SA, Rixensart (BE)
Filed on Jan. 19, 2023, as Appl. No. 18/098,949.
Application 18/098,949 is a continuation of application No. 16/768,402, granted, now 11,591,364, previously published as PCT/EP2018/083234, filed on Nov. 30, 2018.
Claims priority of provisional application 62/593,581, filed on Dec. 1, 2017.
Claims priority of application No. 17209780 (EP), filed on Dec. 21, 2017.
Prior Publication US 2023/0272000 A1, Aug. 31, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/39 (2006.01); A61K 39/00 (2006.01); A61K 39/12 (2006.01); A61K 39/25 (2006.01); C07J 63/00 (2006.01); C12N 7/00 (2006.01)
CPC C07J 63/008 (2013.01) [A61K 39/00 (2013.01); A61K 39/12 (2013.01); A61K 39/25 (2013.01); A61K 39/39 (2013.01); C12N 7/00 (2013.01); A61K 2039/55555 (2013.01); A61K 2039/55577 (2013.01); C12N 2710/16734 (2013.01); C12N 2760/18534 (2013.01)] 18 Claims
 
1. An adjuvant composition comprising a liposomal formulation comprising a saponin extract; the saponin extract comprising at least 93% of QS-21 main peak, as determined by ultraviolet (UV) light absorbance at 214 nm wavelength, and 0.25-3% of 2018 component, as determined by the UV light absorbance at the 214 nm wavelength; the QS-21 main peak comprising:

OG Complex Work Unit Chemistry
and the 2018 component comprising:

OG Complex Work Unit Chemistry